AKTX - Company ID 0001541157
Akari Therapeutics Plc (AKTX) reported net income of -$17.30M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$17.30M | +12.6% |
| FY 2024 | -$19.80M | -97.8% |
| FY 2023 | -$10.01M | +23.5% |
| FY 2022 | -$13.09M | +24.9% |
| FY 2021 | -$17.42M | -2.0% |
| FY 2020 | -$17.08M | -1.4% |
| FY 2019 | -$16.85M | +17.8% |
| FY 2018 | -$20.50M | +42.1% |
| FY 2017 |
Akari Therapeutics Plc (AKTX) reported net income of -$17.30M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2011 and fiscal 2025, Akari Therapeutics Plc's net income declined from -$2.12M to -$17.30M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$35.40M |
| -95.1% |
| FY 2016 | -$18.14M | +60.0% |
| FY 2015 | -$45.32M | -2226.9% |
| FY 2014 | -$1.95M | +46.2% |
| FY 2013 | -$3.62M | +15.2% |
| FY 2012 | -$4.27M | -101.4% |
| FY 2011 | -$2.12M | - |